

Regulation of global and specific mRNA translation by the mTOR signaling pathway

Neethi Nandagopal¹ and Philippe P Roux^{1,2,*}

¹Institute for Research in Immunology and Cancer (IRIC); Université de Montréal; Montréal, Québec, Canada; ²Department of Pathology and Cell Biology; Faculty of Medicine; Université de Montréal; Montréal, Québec, Canada

Keywords: mTOR, mRNA translation, mTORC1, protein synthesis, rapamycin

Abbreviations: 4E-BP, eIF4E-binding protein; TOP, terminal oligopyrimidine; eEF, eukaryotic elongation factor; eIF, eukaryotic initiation factor; ERK, extracellular signal-regulated kinase; mTOR, mammalian/mechanistic target of rapamycin; mTORC1, mTOR complex 1; mTORC2, mTOR complex 2; PDCD4, programmed cell death protein 4; PI3K, phosphatidylinositol 3-phosphate kinase; PKC, protein kinase C; Raptor, regulatory-associated protein of mTOR; Rictor, rapamycin-insensitive companion of mTOR; rp, ribosomal protein; S6K, p70 ribosomal S6 kinase

The translation of mRNA into polypeptides is a key step in eukaryotic gene expression. Translation is mostly controlled at the level of initiation, which is partly regulated by the mammalian/mechanistic target of rapamycin (mTOR) signaling pathway. Whereas mTOR controls global protein synthesis through specific effector proteins, its role in the translation of select groups of mRNAs, such as those harboring a terminal oligopyrimidine (TOP) tract at their 5' end, remains more enigmatic. In this article, we describe the current knowledge on the role of mTOR in global mRNA translation, but also focus on the potential molecular mechanisms underlying the regulation of specific translational programs.

Introduction

The translation of mRNA into polypeptides requires substantial cellular resources,¹ and as such, cells have evolved complex mechanisms to tightly regulate this process. Protein synthesis is frequently deregulated in cancer cells to support aberrant cell growth and proliferation.² Consistent with this, intense efforts are currently being deployed to identify therapeutic agents that would target components of the translational machinery.³ Translation is mostly controlled at the initiation step, during which the eukaryotic small 40S ribosomal subunit is recruited to the 5'-terminal m⁷G[5']ppp[5']N-cap structure of mRNA (where N can be any nucleotide).⁴ This step is facilitated by several eukaryotic translation initiation factors (eIFs) and is partly regulated by the mammalian/mechanistic target of rapamycin (mTOR) signaling pathway.⁵ The latter senses and responds to nutrient availability, energy sufficiency, stress and mitogens to modulate protein synthesis.⁶ In this article, we will cover the mechanisms of cap-

dependent translation, but also discuss what is known about the role of mTOR in the translation of specific subsets of mRNAs in light of recent findings.

Regulation of cap-dependent translation by mTOR signaling

Under favorable growth conditions, mTOR promotes assembly of the eukaryotic translation initiation factor 4F (eIF4F) complex at the 5' end of mRNA (Fig. 1), which facilitates the recruitment of the ribosome and subsequent translation of the transcript.⁷ eIF4F is a heterotrimeric protein complex, consisting of the cap-binding protein eIF4E, the large scaffolding protein eIF4G and the DEAD (Asp-Glu-Ala-Asp)-box RNA helicase eIF4A (also known as DDX2).⁸ eIF4E directly binds to the m⁷G-cap structure and is required for the cap-dependent translation of all nuclear-encoded transcripts.⁹ eIF4G interacts with several proteins, including the large multisubunit protein eIF3 within the 43S pre-initiation complex (PIC), thereby bridging the small ribosomal subunit to the mRNA.⁷ Following recruitment and formation of a 48S complex, the ribosome scans the mRNA towards the initiation codon, a process that is facilitated by the ability of eIF4A to unwind potential secondary structures in the 5' untranslated region (5' UTR) of mRNA.^{10,11} Whereas the intrinsic helicase activity of eIF4A is weak,¹² this can be stimulated by its association with the eIF4F complex, as well as with its regulatory factors eIF4B and eIF4H.¹³ eIF4G also interacts with the poly (A)-binding protein (PABP), which associates with the 3' end of mRNA and allows circularization of the transcript to promote its translation.¹⁴ Recruitment of the 60S ribosomal subunit at the initiation codon results in formation of a translation-competent 80S ribosome that begins the elongation of a new polypeptide chain. Translation elongation is also partly regulated at the level of the eukaryotic elongation factor 2 (eEF2) by mTOR signaling, but this has been thoroughly reviewed elsewhere.¹⁵

The protein Ser/Thr kinase mTOR is the catalytic subunit of 2 functionally and structurally distinct multiprotein complexes

*Correspondence to: Philippe P Roux; Email: philippe.roux@umontreal.ca
Submitted: 07/10/2014; Revised: 08/22/2014; Accepted: 10/29/2014
<http://dx.doi.org/10.4161/21690731.2014.983402>




Figure 1. Schematic representation of mTORC1 signaling to the translational machinery. Growth factors and hormones stimulate mTORC1 activity via the Ras/MAPK and PI3K/Akt signaling pathways. mTORC1 is also activated by amino acids, and inactivated by energy depletion and hypoxia. mTORC1 promotes mRNA translation by regulating the 4E-BPs and S6Ks, which in turn modulate downstream effector proteins such as PDCD4 and eIF4B. Phosphorylation of the 4E-BPs by mTORC1 leads to their dissociation from eIF4E, thereby stimulating assembly of the eIF4F complex. The helicase activity associated with the eIF4F complex is thought to be critical for the unwinding of secondary structures within the mRNA 5'UTR, thereby facilitating scanning of the ribosome toward the initiation codon. The S6Ks and RSKs are thought to modulate eIF4A activity by phosphorylating eIF4B and the tumor suppressor PDCD4. The MNKs are recruited via eIF4G and directly phosphorylate eIF4E. mRNAs which contain a 5' terminal oligopyrimidine (TOP) motif are dependent on mTORC1 activity for their translation. Several RNA-binding proteins were suggested to bind to the TOP motif and regulate TOP mRNA translation, including the La-related protein 1 (LARP1).

known as mTOR complex 1 (mTORC1) and complex 2 (mTORC2), which are defined by the components Raptor (regulatory-associated protein of mTOR) and Rictor (rapamycin-insensitive companion of mTOR), respectively.^{16,17} Both Raptor and Rictor serve as necessary scaffolds that contribute to the integrity of each complex and facilitate the recruitment of mTOR substrates. Whereas mTORC1 controls several anabolic processes required for cell growth and proliferation, such as protein, lipid and nucleotide synthesis,^{6,18} mTORC2 regulates the activity of several AGC (protein kinase A, G and C) family members (e.g., Akt, SGK1, PKC α) that are involved in cell survival and cytoskeletal reorganization.¹⁹ While the central role of mTOR in protein synthesis is largely attributed to mTORC1,^{5,20} mounting evidence suggests that mTORC2 may play a role in cotranslational processing or maturation of nascent polypeptides as they emerge from the ribosome.^{21,22} mTORC1 coordinates mRNA translation by phosphorylating components of the translational machinery, including its 2 best characterized substrates: the eIF4E-binding proteins (4E-BPs) and the ribosomal S6 kinases (S6Ks) 1 and 2 (Fig. 1).^{5,23,24} Using pharmacological inhibitors and genetic models, the functions of the 4E-BPs and S6Ks can be separated in cells, with the 4E-BPs playing comparatively more

important roles in the regulation of cell proliferation.²⁵ Mammals have 3 4E-BP isoforms (4E-BP1, 2 and 3) which are small proteins that repress mRNA translation at the initiation step by interfering with eIF4F complex assembly.^{26,27} In quiescent cells, the 4E-BPs are kept in a hypophosphorylated state and strongly associate with eIF4E, thereby preventing eIF4G binding and eIF4F assembly. Once activated, mTORC1 phosphorylates Thr37/46 in human 4E-BP1, which are priming sites for subsequent phosphorylation at Ser65 and Thr70.^{28,29} These phosphorylation events lead to 4E-BP1 release from eIF4E and subsequent initiation of translation.²⁷ While these regulatory events are thought to be the principal means by which mTORC1 controls global protein synthesis, cells do not respond equally to the inhibition of mTOR.^{30,31} A potential explanation for this comes from findings that the level of expression of the 4E-BPs relative to eIF4E determines the response of cells to mTOR inhibitors.^{25,32} Given that the ratio of eIF4E to the 4E-BPs may differ between cell types, this provides a likely explanation for the differing susceptibility of cancer cells to mTOR inhibitors.³² Additional protein kinases have been shown to regulate phosphorylation of the 4E-BPs, including GSK3 β and CK1 ϵ ,^{33,34} but their relevance in oncogene- and growth factor-induced protein synthesis remains unknown at the moment.

Translational Regulation of “eIF4E-sensitive” Transcripts

Whereas mTORC1 controls global protein synthesis by regulating eIF4F assembly, it also preferentially stimulates the translation of select groups of mRNAs through mechanisms that remain elusive. Among these mRNA subsets are transcripts that contain relatively long and structured 5' UTRs, also referred to as “eIF4E-sensitive” mRNAs (Fig. 1).³⁵ These include several mRNAs encoding proteins involved in cell survival and proliferation,²⁵ such as cyclins,³⁶ ornithine decarboxylase (ODC),³⁷ VEGF³⁸ and Myc.³⁹ Unlike housekeeping mRNAs, which typically do not possess structured 5' UTRs (e.g., GAPDH and β -actin), the majority of eIF4E-sensitive mRNAs have long and highly structured 5' UTRs.^{35,40,41} This feature makes them more dependent on the unwinding activity of eIF4A within the eIF4F complex,⁴² and thus highly sensitive to the levels of eIF4E in the cell. eIF4E was also found to promote eIF4A activity by binding to an autoinhibitory domain of eIF4G, providing additional means by which eIF4E selectively stimulates the translation of highly structured mRNAs.⁴³ Consistent with this, eIF4E has been shown to be overexpressed in many types of cancer, and its expression often correlates with disease progression.⁴⁴ Recently, another subset of mRNAs encoding proteins involved in mitochondrial function and biogenesis has been shown to be sensitive to eIF4E,⁴⁵ but these do not appear to have long 5'UTRs and the mechanisms responsible for their eIF4E sensitivity remains mostly uncharacterized.

As mTORC1 directly controls assembly of the eIF4F complex, its activity is thought to be particularly important for the translation of “eIF4E-sensitive” transcripts. In addition to the

4E-BPs, mTORC1 regulates eIF4A activity via the S6Ks.⁵ Programmed cell death protein 4 (PDCD4) is a binding partner of eIF4A that inhibits translation initiation by preventing assembly of eIF4F complexes.⁴⁶ Phosphorylation of a phosphodegron motif within PDCD4 by the S6Ks was shown to promote its ubiquitination and proteasomal degradation.⁴⁷ The S6Ks also phosphorylate eIF4B, a co-factor of eIF4A.⁴⁸ It was found that eIF4B phosphorylation promotes its recruitment to the eIF4F complex and thereby facilitates cap-dependent translation.⁴⁹⁻⁵¹ These regulatory events were shown to promote the translation of several mRNAs with structured 5'UTRs, including those transcripts encoding proteins involved in cell proliferation (Cdc25C, Myc, ODC) and survival (Bcl2 and XIAP).⁵² Additional AGC family members have been shown to similarly regulate both PDCD4 and eIF4B, including RSK (p90 ribosomal S6 kinase) and Akt,^{50,53,54} underscoring the importance of regulating eIF4F activity in the promotion of different gene expression programs.

In higher eukaryotes, eIF4E is phosphorylated on Ser209 in response to stress and mitogen stimulation,⁵⁵ and this phosphorylation event was shown to be mediated by the MAPK-interacting kinases (MNK1 and 2).^{56,57} To phosphorylate eIF4E, the MNKs are recruited to the eIF4F complex via a direct interaction with the C-terminal region of eIF4G.⁵⁸ Although phosphorylation of eIF4E does not have a major impact on global translation rates, it was found to stimulate the translation of a subset of mRNAs encoding proteins involved in survival (e.g., Mcl1)⁵⁹ and tumor invasion (e.g., Snail, MMP-3).^{60,61} Translational regulation of *Snail* and *MMP-3* mRNAs was found to promote epithelial-to-mesenchymal transition (EMT), pointing to a role for eIF4E phosphorylation in cancer metastasis.⁶⁰ However, the precise mechanisms by which eIF4E phosphorylation affects the translation of these transcripts remain to be determined.

Translational control of TOP mRNAs

A second group of mRNAs, harboring a terminal oligopyrimidine (TOP) tract at their 5' end, was shown to be particularly sensitive to mTOR inhibitors.⁶² These mRNAs encode for components of the translational apparatus, such as ribosomal proteins and elongation factors.^{63,64} The 5'TOP sequence consists of a cytosine at the penultimate nucleotide position followed by a stretch of 4–14 pyrimidines (Fig. 1).^{63,64} The translation of TOP mRNAs is highly sensitive to stress and growth conditions, and behaves as an “all-or-none” phenomenon. Recent studies using high-resolution transcriptome-scale ribosome profiling have confirmed that the translation of TOP mRNAs is highly sensitive to mTOR inhibitors,^{30,31} but the mechanisms by which this occurs still remain unclear.⁶⁵ These studies demonstrated that the selective regulation of TOP mRNAs by mTORC1 depends on the regulation of eIF4E by the 4E-BPs, as the deletion of the latter rendered TOP mRNA translation resistant to mTORC1 inhibition.^{30,31} While these data suggest that the 4E-BPs are required for TOP mRNA translation, another study has shown that hypoxia and other types of stresses suppress TOP mRNA translation independently of the 4E-BPs.⁶⁶ The variance

between studies can be partially explained by differing experimental conditions, nevertheless it does suggest that additional factors may be required for TOP mRNA translation in a context-dependent manner.⁶⁵

Several candidate proteins have been proposed over the years as potential modulators of TOP mRNAs, including the abundant La antigen (also known as La-related protein 3 [LARP3]).⁶⁷⁻⁶⁹ LARP3 was shown to directly interact with mRNAs containing a 5' TOP motif within actively translating polysomes, suggesting that it plays a positive role in TOP mRNA translation.⁶⁷ The RNA-binding protein AUF1 (AU-rich element RNA-binding protein 1) was also found to interact with the 5' TOP sequence, but in this case AUF1 binding correlated with translational repression of TOP mRNAs.⁷⁰ Similarly, the stress granule-associated TIA-1 (T-cell-restricted Intracellular Antigen-1) and TIAR (TIA-1-related protein) were found to assemble at the 5' end of TOP mRNAs and inhibit their translation.⁷¹ This translational suppression required the inactivation of mTOR signaling, suggesting a molecular mechanism by which availability of nutrients may redirect limited cellular resources during suboptimal growth conditions.

In a recent report from our group, we showed that the La-related protein 1 (LARP1) associates with TOP mRNAs and facilitates their translation in cells.⁷² This protein was previously shown to associate with and promote the stability of TOP mRNAs,⁷³ suggesting that LARP1 may regulate TOP mRNAs at different levels to control their expression in cells. Interestingly, 2 studies aiming to characterize the mTOR phosphoproteome repertoire have identified LARP1 as a potential mTORC1 phosphorylation substrate.^{74,75} This finding was recently corroborated using both *in vitro* and *in vivo* phosphorylation assays,⁷⁶ confirming LARP1 as a *bona fide* mTORC1 substrate.⁷⁷ Consistent with this, LARP1 was found to interact with the mTORC1-specific component Raptor, suggesting that LARP1 is an mTORC1-specific cell growth effector.⁷² At this point in time, the biological significance of LARP1 phosphorylation by mTORC1 remains unknown, but results suggest that these phosphorylation events may positively regulate LARP1 function, perhaps by modulating its interaction with mRNA. LARP1 may be one of the many unrecognized regulators of specific mRNA translation downstream of mTORC1, which may provide additional means for promoting or suppressing the translation of specific subsets of mRNAs.

Local translation of TOP mRNAs in Activity-dependent Protein Synthesis

In addition to playing roles in determining the type of transcripts to be translated, mTORC1 regulates mRNA translation in space and time.^{78,79} This is likely to be particularly important for synaptic plasticity, such as during the late phase of long-term potentiation (L-LTP), which requires local increases in protein synthesis in response to synaptic activity.⁸⁰⁻⁸² Neuronal mTORC1 becomes activated in response to different stimulation paradigms (i.e., forskolin, high-frequency stimulation, mGluR

agonists), and its inhibition by rapamycin was found to block long-lasting synaptic changes and memory consolidation in different animal models.⁷⁸ Notably, a number of studies have documented an elevation in the levels of elongation factors eEF1A and eEF2, as well as ribosomal protein S6, in response to synaptic activity in both mammals and *Aplysia*.⁸³⁻⁸⁸ All of these proteins are encoded by TOP mRNAs,⁶⁴ suggesting that mTORC1 may participate in synaptic plasticity by locally increasing the availability of translation factors and other components of the translational apparatus.⁷⁸ Evidence for this comes from the observation that TOP mRNAs are transported into dendrites and axons where they are locally translated in an mTORC1-dependent manner.^{88,89} In fact, TOP mRNAs represent some of the most abundant transcripts localized within these structures.^{90,91}

While it seems unlikely that new ribosomes are assembled in this compartment, as this process is thought to strictly occur in the nucleolus,⁹² the translation of TOP mRNAs may serve to selectively replace or replete translation factors and ribosomal proteins during times of increased demand in protein synthesis.⁷⁸ Another possibility is that certain elongation factors encoded by TOP mRNAs may be present in dendrites and axons in limiting amounts, such that increasing their expression by promoting TOP mRNA translation would significantly increase overall translation rates. Alternatively, certain proteins encoded by TOP mRNAs may serve extraribosomal functions that may or may not be specific to neuronal cells.⁷⁸ Our results implicating LARP1 in TOP mRNA translation suggest that this protein may also be involved in local mRNA translation.⁷² Based on mRNA expression profiles, LARP1 is ubiquitously expressed with relatively high expression levels in the nervous system. One possibility is that LARP1 may be required for TOP mRNA translation in specific compartments, such as dendrites and axons, but the potential role of LARP1 in the nervous system remains highly speculative at the moment.

mTORC1 Regulates the Cap Recruitment of a Network of Translational Regulators

Using m⁷G-cap affinity chromatography and quantitative mass spectrometry (MS), our group has globally surveyed proteins that directly or indirectly interact with the 5' mRNA cap structure.⁷² This search has led to the identification of ~160 distinct proteins, from which a majority was found to co-purify based on protein-protein interactions (their purification was resistant to nuclease treatment). This characterization was performed under conditions where mTOR activity was either increased by insulin treatment or reduced using an mTOR inhibitor, which revealed an orchestrated network of interactions to the 5' mRNA cap structure that is dependent on mTOR activity. As expected, we found that many known translational regulators were recruited to the 5' mRNA cap in a manner that was dependent on mTOR activity, including eIF4G, eIF4A, and eIF3 isoforms, as well as PABP. We identified 4E-BP1 and 2 as the only 2 proteins whose interactions negatively correlated with mTOR activity,⁷² suggesting that they may be responsible for the

displacement of all eIF4E-dependent proteins upon mTOR inhibition. To address this, we compared mTOR responsiveness between wild-type and double *4E-BP1/2* knockout fibroblasts, and found that all mTOR-dependent regulations were lost in cells lacking the 4E-BPs.⁷² These results underscore the role of the 4E-BPs in regulating proteins' access to eIF4E, and suggest that the effects of mTOR inhibitors on global protein synthesis are highly dependent on the 4E-BPs, as reported.²⁵ As indicated above, this may help in explaining some of the discrepancies in the literature regarding the effects of mTOR inhibitors.

In addition to known translational regulators, our results indicate that many proteins with uncharacterized roles in translation are recruited to eIF4E in response to mTOR stimulation.⁷² Notably, many of these proteins were found to contain a RNA recognition motif, suggesting that they regulate some aspects of mRNA metabolism in a manner that is dependent on mTOR activity. These include several hnRNPs (heterogeneous nuclear ribonucleoproteins), such as hnRNP A1, F, U and R, which are RNA-binding proteins with multiple roles in mRNA metabolism.⁹³ A key characteristic of hnRNPs is that they undergo nucleo-cytoplasmic shuttling and thus likely participates in mRNA transport.⁹⁴ Each hnRNP binds to specific ribonucleotide sequences and therefore associates with distinct subsets of mRNA.⁹³ Our results indicate that mTOR stimulates the recruitment of some hnRNP isoforms to the 5' mRNA cap,⁷² which may provide a regulated mechanism for the selective recruitment of mRNAs to the translational machinery. Consistent with this possibility, is the fact that hnRNP A1 and F have been shown to regulate the translation of specific mRNAs^{95,96}; however, the involvement of mTOR in this process is currently unknown.

Our results also indicate that several RNA helicases are recruited to the 5' mRNA cap structure in response to mTOR activation, including DDX3, DDX6, DHX9, DDX17 and DDX36.⁷² These RNA helicases may assist eIF4A during the initiation step to enhance the process of ribosomal scanning on structured mRNAs,⁹⁷ as was recently described for the DEAH (Asp-Glu-Ala-His)-box protein DHX29.⁹⁸ The DEAD-box helicase DDX3 is not essential for global translation, but is required for the translation of specific transcripts (e.g., *Cyclin E1*) that contain secondary structures within their 5' UTRs.^{99,100} We found that mTOR promotes the recruitment of DDX3 to the 5' mRNA cap in a 4E-BP1/2-dependent manner,⁷² suggesting a mechanism whereby mTOR activity is required for the translation of DDX3-bound transcripts. DDX6 (also known as RCK or p54) is a highly conserved DEAD-box helicase that contributes to global and transcript-specific mRNA storage, translational repression, and decay.¹⁰¹ Recently, DDX6 was found to participate in the miRNA-mediated silencing of specific transcripts,¹⁰² suggesting that in this case mTOR may participate in the translational repression of DDX6-bound transcripts. The highly conserved protein DHX9 (also known as RNA helicase A; RHA) was also recognized to participate in translation initiation.¹³ It was shown to assist eIF4A in the unwinding of secondary structures within the 5' UTR of specific mRNAs (e.g., *JUND*).^{103,104} At present, there is no

evidence that DDX17 or DDX36 participate in translational regulation, but our results highly suggest that they may be unrecognized modulators of translation initiation.

Conclusions and Perspectives

Recent studies of the transcriptome have demonstrated that steady-state mRNA levels show low concordance with the cellular proteome,^{105,106} suggesting that translational regulation plays a major role in gene expression. Consistent with this, translational control was shown to regulate many aspects of life, including embryonic development, immunity, metabolism and the maintenance of normal physiology.¹⁰⁷⁻¹⁰⁹ Based on the involvement of several oncogenic signaling pathways in the regulation of protein synthesis,²⁴ it is not surprising that deregulation of mRNA translation can contribute to cancer.^{110,111} Many studies have reported the overexpression of different eIFs in cancer,¹¹² further suggesting that many components of the translational machinery represent potential targets for therapeutic intervention.³

In addition to global mechanisms of translational regulation, it is now clear that different *cis*-acting elements present on the RNA molecule and their cognate *trans*-acting factors greatly affect translational efficiency. While it has been known for some time that certain subsets of mRNAs are differently affected by mTORC1 signaling, including TOP mRNAs and eIF4E-sensitive transcripts,^{35,62} the molecular properties dictating this selectivity are poorly defined. It goes without saying that many unrecognized mechanisms of specific translation must also exist, and these represent major challenges that would need to be addressed in order to fully understand the complexity of translational regulation. To this end, it will be important to globally determine the specificity of different RNA-binding proteins for their associated mRNAs using crosslinking approaches and high-throughput sequencing.¹¹³ Another important avenue for future studies is to understand cell type-specific regulation of mRNA localization and translation. For example, the localization and upstream regulation of mRNA translation in differentiated neurons is likely to be different from that of highly proliferating cells. Indeed, accumulating evidence suggests that the spatial regulation of mRNA translation can determine biological consequences,¹¹⁴ such as during synaptic plasticity.^{115,116} Elucidation of the molecular mechanisms underlying specific mRNA translation will result in a better understanding of various human diseases, especially those characterized by deregulated mRNA translation, such as diabetes, obesity and cancer to name a few.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank Drs. Wayne Sossin, Ivan Topisirovic and Joseph Tcherkezian for comments on the manuscript.

Funding

Work in the P.P.R. laboratory is supported by grants from the Canadian Institutes for Health Research, the Cancer Research Society, the Human Frontier Science Program, as well as the National

Science and Engineering Research Council. P.P.R. is the Canada Research Chair in Cell Signaling and Proteomics. The Institute for Research in Immunology and Cancer core facilities are supported in part by Le Fonds de Recherche du Québec - Santé.

References

- Buttgereit F, Brand MD. A hierarchy of ATP-consuming processes in mammalian cells. *Biochem J* 1995; 312 (Pt 1):163-7; PMID:7492307
- Stumpf CR, Ruggero D. The cancerous translation apparatus. *Curr Opin Genet Dev* 2011; 21:474-83; PMID:21543223; <http://dx.doi.org/10.1016/j.gde.2011.03.007>
- Malina A, Cencic R, Pelletier J. Targeting translation dependence in cancer. *Oncotarget* 2011; 2:76-88; PMID:21378410
- Shatkin AJ. Capping of eucaryotic mRNAs. *Cell* 1976; 9:645-53; PMID:1017010; [http://dx.doi.org/10.1016/0092-8674\(76\)90128-8](http://dx.doi.org/10.1016/0092-8674(76)90128-8)
- Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. *Nat Rev Mol Cell Biol* 2009; 10:307-18; PMID:19339977; <http://dx.doi.org/10.1038/nrm2672>
- Dibble CC, Manning BD. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. *Nat Cell Biol* 2013; 15:555-64; PMID:23728461; <http://dx.doi.org/10.1038/ncb2763>
- Jackson RJ, Hellen CU, Pestova TV. The mechanism of eukaryotic translation initiation and principles of its regulation. *Nat Rev Mol Cell Biol* 2010; 11:113-27; PMID:20094052; <http://dx.doi.org/10.1038/nrm2838>
- Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. *Ann Rev Biochem* 1999; 68:913-63; PMID:10872469; <http://dx.doi.org/10.1146/annurev.biochem.68.1.913>
- Topisirovic I, Svitkin YV, Sonenberg N, Shatkin AJ. Cap and cap-binding proteins in the control of gene expression. *Wires Rna* 2011; 2:277-98; PMID:21957010; <http://dx.doi.org/10.1002/wrna.52>
- Rozen F, Edery I, Meerovitch K, Dever TE, Merrick WC, Sonenberg N. Bidirectional RNA helicase activity of eucaryotic translation initiation factors 4A and 4F. *Mol Cell Biol* 1990; 10:1134-44; PMID:2304461
- Pause A, Methot N, Svitkin Y, Merrick WC, Sonenberg N. Dominant negative mutants of mammalian translation initiation factor eIF-4A define a critical role for eIF-4F in cap-dependent and cap-independent initiation of translation. *EMBO J* 1994; 13:1205-15; PMID:8131750
- Rogers GW, Jr., Richter NJ, Merrick WC. Biochemical and kinetic characterization of the RNA helicase activity of eucaryotic initiation factor 4A. *J Biol Chem* 1999; 274:12236-44; PMID:10212190; <http://dx.doi.org/10.1074/jbc.274.18.12236>
- Parsyan A, Svitkin Y, Shahbazian D, Gkogkas C, Lasko P, Merrick WC, Sonenberg N. mRNA helicases: the tacticians of translational control. *Nat Rev Mol Cell Biol* 2011; 12:235-45; PMID:21427765; <http://dx.doi.org/10.1038/nrm3083>
- Kahvejian A, Svitkin YV, Sukarieh R, M'Boutchou MN, Sonenberg N. Mammalian poly(A)-binding protein is a eucaryotic translation initiation factor, which acts via multiple mechanisms. *Genes Dev* 2005; 19:104-13; PMID:15630022; <http://dx.doi.org/10.1101/gad.1262905>
- Kenney JW, Moore CE, Wang X, Proud CG. Eucaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles. *Adv Biol Regulation* 2014; 55C:15-27; <http://dx.doi.org/10.1016/j.jbior.2014.04.003>
- Caron E, Ghosh S, Matsuoka Y, Ashton-Beaucage D, Therrien M, Lemieux S, Perreault C, Roux PP, Kitano H. A comprehensive map of the mTOR signaling network. *Mol Sys Biol* 2011; 6:453.
- Laplante M, Sabatini DM. mTOR signaling in growth control and disease. *Cell* 2012; 149:274-93; PMID:22500797; <http://dx.doi.org/10.1016/j.cell.2012.03.017>
- Howell JJ, Ricourt SJ, Ben-Sahra I, Manning BD. A growing role for mTOR in promoting anabolic metabolism. *Biochem Soc Trans* 2013; 41:906-12; PMID:23863154; <http://dx.doi.org/10.1042/BST20130041>
- Oh WJ, Jacinto E. mTOR complex 2 signaling and functions. *Cell Cycle* 2011; 10:2305-16; PMID:21670596; <http://dx.doi.org/10.4161/cc.10.14.16586>
- Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. *Cell* 2009; 136:731-45; PMID:19239892; <http://dx.doi.org/10.1016/j.cell.2009.01.042>
- Zinzalla V, Stracka D, Opplinger W, Hall MN. Activation of mTORC2 by association with the ribosome. *Cell* 2011; 144:757-68; PMID:21376236; <http://dx.doi.org/10.1016/j.cell.2011.02.014>
- Oh WJ, Wu CC, Kim SJ, Facchinetti V, Julien LA, Finlan M, Roux PP, Su B, Jacinto E. mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide. *EMBO J* 2010; 29:3939-51; PMID:21045808; <http://dx.doi.org/10.1038/emboj.2010.271>
- Foster KG, Fingar DC. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. *J Biol Chem* 2010; 285:14071-7; PMID:20231296; <http://dx.doi.org/10.1074/jbc.R109.094003>
- Roux PP, Topisirovic I. Regulation of mRNA translation by signaling pathways. *Cold Spring Harbor Perspect Biol* 2012; 4; PMID:22888049; <http://dx.doi.org/10.1101/cshperspect.a012252>
- Dowling RJ, Topisirovic I, Alain T, Bidnost M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj A, Liu Y, et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. *Science* 2010; 328:1172-6; PMID:20508131; <http://dx.doi.org/10.1126/science.1187532>
- Lin TA, Kong X, Haystead TA, Pause A, Belsham G, Sonenberg N, Lawrence JC Jr. PHAS-I as a link between mitogen-activated protein kinase and translation initiation. *CA>Science* 1994; 266:653-6
- Pause A, Belsham GJ, Gingras AC, Donze O, Lin TA, Lawrence JC, Jr., Sonenberg N. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. *Nature* 1994; 371:762-7; PMID:7935836; <http://dx.doi.org/10.1038/371762a0>
- Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R, Sonenberg N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. *Genes Dev* 1999; 13:1422-37; PMID:10364159; <http://dx.doi.org/10.1101/gad.13.11.1422>
- Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, Polakiewicz RD, Wyslouch-Cieszyńska A, Aebersold R, Sonenberg N, et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. *Genes Dev* 2001; 15:2852-64; PMID:11691836; <http://dx.doi.org/10.1101/gad.887201>
- Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Jones MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. *Nature* 2012; 485:55-61; PMID:22367541; <http://dx.doi.org/10.1038/nature10912>
- Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM. A unifying model for mTORC1-mediated regulation of mRNA translation. *Nature* 2012; 485:109-13; PMID:22552098; <http://dx.doi.org/10.1038/nature11083>
- Alain T, Morita M, Fonseca BD, Yanagiya A, Siddiqui N, Bhat M, Zammit D, Marcus V, Metrakos P, Voyer LA, et al. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. *Cancer Res* 2012; 72:6468-76; PMID:23100465; <http://dx.doi.org/10.1158/0008-5472.CAN-12-2395>
- Shin S, Wolgamott L, Roux PP, Yoon SO. Casein kinase Iepsilon promotes cell proliferation by regulating mRNA translation. *Cancer Res* 2014; 74:201-11; PMID:24247720; <http://dx.doi.org/10.1158/0008-5472.CAN-13-1175>
- Shin S, Wolgamott L, Tcherkezian J, Vallabhapurapu S, Yu Y, Roux PP, Yoon SO. Glycogen synthase kinase-3beta positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1. *Oncogene* 2013; 33:1690-9
- Koromilas AE, Lazaris-Karatzas A, Sonenberg N. mRNAs containing extensive secondary structure in their 5' non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E. *EMBO J* 1992; 11:4153-8; PMID:1396596
- Rosenwald IB, Kaspar R, Rousseau D, Gehrke L, Leboulch P, Chen JJ, Schmidt EV, Sonenberg N, London IM. Eucaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. *J Biol Chem* 1995; 270:21176-80; PMID:7673150; <http://dx.doi.org/10.1074/jbc.270.36.21176>
- Fagan RJ, Lazaris-Karatzas A, Sonenberg N, Rozen R. Translational control of ornithine aminotransferase. Modulation by initiation factor eIF-4E. *J Biol Chem* 1991; 266:16518-23; PMID:1909329
- Kevil CG, De Benedetti A, Payne DK, Coe LL, Laroux FS, Alexander JS. Translational regulation of vascular permeability factor by eucaryotic initiation factor 4E: implications for tumor angiogenesis. *Int J Cancer J Int Du Cancer* 1996; 65:785-90; PMID:8631593; [http://dx.doi.org/10.1002/\(SICI\)1097-0215\(19960315\)65:6%3c785::AID-IJC14%3e3.0.CO;2-3](http://dx.doi.org/10.1002/(SICI)1097-0215(19960315)65:6%3c785::AID-IJC14%3e3.0.CO;2-3)
- Zimmer SG, DeBenedetti A, Graff JR. Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. *Anticancer Res* 2000; 20:1343-51; PMID:10928042
- De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. *Oncogene* 2004; 23:3189-99; PMID:15094768; <http://dx.doi.org/10.1038/sj.onc.1207545>
- Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. *Nat Rev Cancer* 2010; 10:254-66; PMID:20332778; <http://dx.doi.org/10.1038/nrc2824>
- Svitkin YV, Pause A, Haghghat A, Pyronnet S, Witherell G, Belsham GJ, Sonenberg N. The requirement for eucaryotic initiation factor 4A (eIF4A) in translation is in direct proportion to the degree of mRNA 5' secondary structure. *Rna* 2001; 7:382-94; PMID:11333019; <http://dx.doi.org/10.1017/S135583820100108X>
- Feoktistova K, Tuvshintogs E, Do A, Fraser CS. Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity. *Proc Natl Acad*

- Sci U S A 2013; 110:13339-44; PMID:23901100; <http://dx.doi.org/10.1073/pnas.1303781110>
44. Jia Y, Polunovsky V, Bitterman PB, Wagner CR. Cap-dependent translation initiation factor eIF4E: an emerging anticancer drug target. *Med Res Rev* 2012; 32:786-814; PMID:22495651; <http://dx.doi.org/10.1002/med.21260>
 45. Morita M, Gravel SP, Chenard V, Sikstrom K, Zheng L, Alain T, Gandin V, Avizonis D, Arguello M, Zakaria C, et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. *Cell Metab* 2013; 18:698-711; PMID:24206664; <http://dx.doi.org/10.1016/j.cmet.2013.10.001>
 46. Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, Lockett SJ, Sonenberg N, Colburn NH. The transformation suppressor Pdc4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. *Mol Cell Biol* 2003; 23:26-37; PMID:12482958; <http://dx.doi.org/10.1128/MCB.23.1.26-37.2003>
 47. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. *Science* 2006; 314:467-71; PMID:17053147; <http://dx.doi.org/10.1126/science.1130276>
 48. Rogers GW, Jr., Komar AA, Merrick WC. eIF4A: the godfather of the DEAD box helicases. *Prog Nucleic Acid Res Mole Biol* 2002; 72:307-31; PMID:12206455; [http://dx.doi.org/10.1016/S0079-6603\(02\)72073-4](http://dx.doi.org/10.1016/S0079-6603(02)72073-4)
 49. Raught B, Peiretti F, Gingras AC, Livingstone M, Shabbazian D, Mayeur GL, Polakiewicz RD, Sonenberg N, Hershey JW. Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. *EMBO J* 2004; 23:1761-9; PMID:15071500; <http://dx.doi.org/10.1038/sj.emboj.7600193>
 50. Shabbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J, Hershey JW, Blenis J, Pende M, Sonenberg N. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. *EMBO J* 2006; 25:2781-91; PMID:16763566; <http://dx.doi.org/10.1038/sj.emboj.7601166>
 51. Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. *Cell* 2005; 123:569-80; PMID:16286006; <http://dx.doi.org/10.1016/j.cell.2005.10.024>
 52. Shabbazian D, Parsyan A, Petroulakis E, Topisirovic I, Martineau Y, Gibbs BF, Svitkin Y, Sonenberg N. Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B. *Mol Cell Biol* 2010; 30:1478-85; PMID:20086100; <http://dx.doi.org/10.1128/MCB.01218-09>
 53. Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM, Pekarsky Y. Akt phosphorylates and regulates Pdc4 tumor suppressor protein. *Cancer Res* 2005; 65:11282-6; PMID:16357133; <http://dx.doi.org/10.1158/0008-5472.CAN-05-3469>
 54. Galan JA, Geraghty KM, Lavoie G, Kanshin E, Tcherkezian J, Calabrese V, Jeschke GR, Turk BE, Ballif BA, Blenis J, et al. Phosphoproteomic analysis identifies the tumor suppressor PDCD4 as a RSK substrate negatively regulated by 14-3-3. *Proc Natl Acad Sci U S A* 2014; 111:E2918-27; PMID:25002506; <http://dx.doi.org/10.1073/pnas.1405601111>
 55. Flynn A, Vries RG, Proud CG. Signalling pathways which regulate eIF4E. *Biochem Soc Trans* 1997; 25:192S.
 56. Scheper GC, Morrice NA, Kleijn M, Proud CG. The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells. *Mol Cell Biol* 2001; 21:743-54; PMID:11154262; <http://dx.doi.org/10.1128/MCB.21.3.743-754.2001>
 57. Knauf U, Tschopp C, Gram H. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. *Mol Cell Biol* 2001; 21:5500-11; PMID:11463832; <http://dx.doi.org/10.1128/MCB.21.16.5500-5511.2001>
 58. Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunter T, Sonenberg N. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. *EMBO J* 1999; 18:270-9; PMID:9878069; <http://dx.doi.org/10.1093/emboj/18.1.270>
 59. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Teruya-Feldstein J, Pelletier J, et al. Dissecting eIF4E action in tumorigenesis. *Genes Dev* 2007; 21:3232-7; PMID:18055695; <http://dx.doi.org/10.1101/gad.1604407>
 60. Robichaud N, Del Rincon SV, Huor B, Alain T, Petrucelli LA, Hearnden J, Goncalves C, Grotteguet S, Spruck CH, Furic L, et al. Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. *Oncogene* 2014; PMID:24909168
 61. Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, Pollak M, Gaboury LA, et al. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. *Proc Natl Acad Sci U S A* 2010; 107:14134-9; PMID:20679199; <http://dx.doi.org/10.1073/pnas.1005320107>
 62. Jefferies HB, Reinhard C, Kozma SC, Thomas G. Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. *Proc Natl Acad Sci U S A* 1994; 91:4441-5; PMID:8183928; <http://dx.doi.org/10.1073/pnas.91.10.4441>
 63. Avni D, Biberman Y, Meyuhos O. The 5' terminal oligopyrimidine tract confers translational control on TOP mRNAs in a cell type- and sequence context-dependent manner. *Nucleic Acids Res* 1997; 25:995-1001; PMID:9023110; <http://dx.doi.org/10.1093/nar/25.5.995>
 64. Meyuhos O. Synthesis of the translational apparatus is regulated at the translational level. *Eur J Biochem / FEBS* 2000; 267:6321-30; PMID:11029573; <http://dx.doi.org/10.1046/j.1432-1327.2000.01719.x>
 65. Gentilella A, Thomas G. Cancer biology: The director's cut. *CA>Nature* 2012; 485:50-1.
 66. Miloslavski R, Cohen E, Avraham A, Iluz Y, Hayouka Z, Kasir J, Mudhasani R, Jones SN, Cybulski N, Ruegg MA, et al. Oxygen sufficiency controls TOP mRNA translation via the TSC-Rheb-mTOR pathway in a 4E-BP-independent manner. *J Mol Cell Biol* 2014; 6:255-66; PMID:24627160; <http://dx.doi.org/10.1093/jmcb/mju008>
 67. Cardinali B, Carissimi C, Gravina P, Pierandrei-Amaldi P. La protein is associated with terminal oligopyrimidine mRNAs in actively translating polysomes. *J Biol Chem* 2003; 278:35145-51; PMID:12840030; <http://dx.doi.org/10.1074/jbc.M300722200>
 68. Crosio C, Boyd PP, Loreni F, Pierandrei-Amaldi P, Amaldi F. La protein has a positive effect on the translation of TOP mRNAs in vivo. *Nucleic Acids Res* 2000; 28:2927-34; PMID:10908356; <http://dx.doi.org/10.1093/nar/28.15.2927>
 69. Pellizzoni L, Cardinali B, Lin-Marq N, Mercanti D, Pierandrei-Amaldi P. A *Xenopus laevis* homologue of the La autoantigen binds the pyrimidine tract of the 5' UTR of ribosomal protein mRNAs in vitro: implication of a protein factor in complex formation. *J Mol Biol* 1996; 259:904-15; PMID:8683593; <http://dx.doi.org/10.1006/jmbi.1996.0368>
 70. Kakegawa T, Ohuchi N, Hayakawa A, Hirata S, Matsuda M, Kogure K, Kobayashi H, Inoue A, Kaspar RL. Identification of AUF1 as a rapamycin-responsive binding protein to the 5'-terminal oligopyrimidine element of mRNAs. *Arch Biochem Biophys* 2007; 465:274-81; PMID:17603996; <http://dx.doi.org/10.1016/j.abb.2007.06.001>
 71. Damgaard CK, Lykke-Andersen J. Translational coregulation of 5'TOP mRNAs by TIA-1 and TIAR. *Genes Dev* 2011; 25:2057-68; PMID:21979918; <http://dx.doi.org/10.1101/gad.17355911>
 72. Tcherkezian J, Cargnello M, Romeo Y, Huttlin EL, Lavoie G, Gygi SP, Roux PP. Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5'TOP mRNA translation. *Genes Dev* 2014; 28:357-71; PMID:24532714; <http://dx.doi.org/10.1101/gad.231407.113>
 73. Aoki K, Adachi S, Homoto M, Kusano H, Koike K, Natsume T. LARP1 specifically recognizes the 3' terminus of poly(A) mRNA. *CA>FEBS Lett* 2013; 587:2173-8; <http://dx.doi.org/10.1016/j.febslet.2013.05.035>
 74. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, Peterson TR, Choi Y, Gray NS, Yaffe MB, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. *CA>Science* 2011; 332:1317-22; PMID:21659604
 75. Yu Y, Yoon SO, Poulgiannis G, Yang Q, Ma XM, Vilen J, Kubica N, Hoffman GR, Cantley LC, Gygi SP, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. *Science* 2011; 332:1322-6; PMID:21659605; <http://dx.doi.org/10.1126/science.1199484>
 76. Kang SA, Pacold ME, Cervantes CL, Lim D, Lou HJ, Ottina K, Gray NS, Turk BE, Yaffe MB, Sabatini DM. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. *Science* 2013; 341:1236566; PMID:23888043; <http://dx.doi.org/10.1126/science.1236566>
 77. Yoon SO, Roux PP. Rapamycin resistance: mTORC1 substrates hold some of the answers. *Curr Biol* 2013; 23:R880-3; PMID:24112984; <http://dx.doi.org/10.1016/j.cub.2013.08.030>
 78. Graber TE, McCamphill PK, Sossin WS. A recollection of mTOR signaling in learning and memory. *Learn Mem* 2013; 20:518-30; PMID:24042848; <http://dx.doi.org/10.1101/lm.027664.112>
 79. Besse F, Ephrussi A. Translational control of localized mRNAs: restricting protein synthesis in space and time. *Nat Rev Mol Cell Biol* 2008; 9:971-80; PMID:19023284; <http://dx.doi.org/10.1038/nrm2548>
 80. Bradshaw KD, Emptage NJ, Bliss TV. A role for dendritic protein synthesis in hippocampal late LTP. *Eur J Neurosci* 2003; 18:3150-2; PMID:14656312; <http://dx.doi.org/10.1111/j.1460-9568.2003.03054.x>
 81. Gkogkas C, Sonenberg N, Costa-Mattioli M. Translational control mechanisms in long-lasting synaptic plasticity and memory. *J Biol Chem* 2010; 285:31913-7; PMID:20693284; <http://dx.doi.org/10.1074/jbc.R110.154476>
 82. Costa-Mattioli M, Sossin WS, Klann E, Sonenberg N. Translational control of long-lasting synaptic plasticity and memory. *Neuron* 2009; 61:10-26; PMID:19146809; <http://dx.doi.org/10.1016/j.neuron.2008.10.055>
 83. Giustetto M, Hegde AN, Si K, Casadio A, Inokuchi K, Pei W, Kandel ER, Schwartz JH. Axonal transport of eukaryotic translation elongation factor alpha mRNA couples transcription in the nucleus to long-term facilitation at the synapse. *Proc Natl Acad Sci U S A* 2003; 100:13680-5; PMID:14578450; <http://dx.doi.org/10.1073/pnas.1835674100>
 84. Tsokas P, Grace EA, Chan P, Ma T, Sealson SC, Iyengar R, Landau EM, Blitzer RD. Local protein synthesis mediates a rapid increase in dendritic elongation factor 1A after induction of late long-term potentiation. *J Neurosci* 2005; 25:5833-43;

- PMID:15958750; <http://dx.doi.org/10.1523/JNEUROSCI.0599-05.2005>
85. Huang F, Chotiner JK, Steward O. The mRNA for elongation factor 1alpha is localized in dendrites and translated in response to treatments that induce long-term depression. *J Neurosci* 2005; 25:7199-209; PMID:16079402; <http://dx.doi.org/10.1523/JNEUROSCI.1779-05.2005>
 86. Carroll M, Dyer J, Sossin WS. Serotonin increases phosphorylation of synaptic eEFB through TOR, but eukaryotic initiation factor 4E levels do not limit somatic cap-dependent translation in aplysia neurons. *Mol Cell Biol* 2006; 26:8586-98; PMID:16982686; <http://dx.doi.org/10.1128/MCB.00955-06>
 87. Carroll M, Warren O, Fan X, Sossin WS. Five-HT stimulates eEF2 dephosphorylation in a rapamycin-sensitive manner in Aplysia neurites. *J Neurochem* 2004; 90:1464-76; PMID:15341530; <http://dx.doi.org/10.1111/j.1471-4159.2004.02634.x>
 88. Tsokas P, Ma T, Iyengar R, Landau EM, Blitzer RD. Mitogen-activated protein kinase upregulates the dendritic translation machinery in long-term potentiation by controlling the mammalian target of rapamycin pathway. *J Neurosci* 2007; 27:5885-94; PMID:17537959; <http://dx.doi.org/10.1523/JNEUROSCI.4548-06.2007>
 89. Gobert D, Topolnik L, Azzi M, Huang L, Badaeux F, Desgroseillers L, Sossin WS, Lacaillle JC. Forskolin induction of late-LTP and up-regulation of 5' TOP mRNAs translation via mTOR, ERK, and PI3K in hippocampal pyramidal cells. *J Neurochem* 2008; 106:1160-74; PMID:18466337; <http://dx.doi.org/10.1111/j.1471-4159.2008.05470.x>
 90. Moccia R, Chen D, Lyles V, Kapuya E, E Y, Kalachikov S, Spahn CM, Frank J, Kandel ER, Barad M, et al. An unbiased cDNA library prepared from isolated Aplysia sensory neuron processes is enriched for cytoskeletal and translational mRNAs. *J Neurosci* 2003; 23:9409-17; PMID:14561869
 91. Poon MM, Choi SH, Jamieson CA, Geschwind DH, Martin KC. Identification of process-localized mRNAs from cultured rodent hippocampal neurons. *J Neurosci* 2006; 26:13390-9; PMID:17182790; <http://dx.doi.org/10.1523/JNEUROSCI.3432-06.2006>
 92. Shaw PJ, Jordan EG. The nucleolus. *Ann Rev Cell Dev Biol* 1995; 11:93-121; PMID:8689574; <http://dx.doi.org/10.1146/annurev.cb.11.110195.000521>
 93. Han SP, Tang YH, Smith R. Functional diversity of the hnRNPs: past, present and perspectives. *Biochem J* 2010; 430:379-92; PMID:20795951; <http://dx.doi.org/10.1042/BJ20100396>
 94. Pinol-Roma S, Dreyfuss G. Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm. *Nature* 1992; 355:730-2; PMID:1371331; <http://dx.doi.org/10.1038/355730a0>
 95. Cammas A, Pileur F, Bonnal S, Lewis SM, Leveque N, Holcik M, Vagner S. Cytoplasmic relocalization of heterogeneous nuclear ribonucleoprotein A1 controls translation initiation of specific mRNAs. *Mol Biol Cell* 2007; 18:5048-59; PMID:17898077; <http://dx.doi.org/10.1091/mbc.E07-06-0603>
 96. Alkan SA, Martincic K, Milcarek C. The hnRNPs F and H2 bind to similar sequences to influence gene expression. *Biochem J* 2006; 393:361-71; PMID:16171461; <http://dx.doi.org/10.1042/BJ20050538>
 97. Pickering BM, Willis AE. The implications of structured 5' untranslated regions on translation and disease. *CA>Semin Cell Dev Biol* 2005; 16:39-47; PMID:15659338
 98. Parsyan A, Shahbazian D, Martineau Y, Petroulakis E, Alain T, Larsson O, Mathonnet G, Tettweiler G, Hellen CU, Pestova TV, et al. The helicase protein DHX29 promotes translation initiation, cell proliferation, and tumorigenesis. *Proc Natl Acad Sci U S A* 2009; 106:22217-22; PMID:20018725; <http://dx.doi.org/10.1073/pnas.0909773106>
 99. Lai MC, Chang WC, Shieh SY, Tarn WY. DDX3 regulates cell growth through translational control of cyclin E1. *Mol Cell Biol* 2010; 30:5444-53; PMID:20837705; <http://dx.doi.org/10.1128/MCB.00560-10>
 100. Soto-Rifo R, Rubilar PS, Limousin T, de Breyne S, Decimo D, Ohlmann T. DEAD-box protein DDX3 associates with eIF4F to promote translation of selected mRNAs. *EMBO J* 2012; 31:3745-56; PMID:22872150; <http://dx.doi.org/10.1038/emboj.2012.220>
 101. Ostareck DH, Naarmann-de Vries IS, Ostareck-Lederer A. DDX6 and its orthologs as modulators of cellular and viral RNA expression. *Wiley interdisciplinary Rev RNA* 2014; PMID:24788243
 102. Chen Y, Boland A, Kuzuoglu-Ozturk D, Bawankar P, Loh B, Chang CT, Weichenrieder O, Izaurralde E. A DDX6-CNOT1 Complex and W-Binding Pockets in CNOT9 Reveal Direct Links between miRNA Target Recognition and Silencing. *Mol Cell* 2014; 54:737-50; PMID:24768540; <http://dx.doi.org/10.1016/j.molcel.2014.03.034>
 103. Hartman TR, Qian S, Bolinger C, Fernandez S, Schoenberg DR, Boris-Lawrie K. RNA helicase A is necessary for translation of selected messenger RNAs. *Nat Struct Mol Biol* 2006; 13:509-16; PMID:16680162; <http://dx.doi.org/10.1038/nsmb1092>
 104. Short JD, Pfarr CM. Translational regulation of the JunD messenger RNA. *J Biol Chem* 2002; 277:32697-705; PMID:12105216; <http://dx.doi.org/10.1074/jbc.M204553200>
 105. Schwanhauser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M. Global quantification of mammalian gene expression control. *Nature* 2011; 473:337-42; PMID:21593866; <http://dx.doi.org/10.1038/nature10098>
 106. Ghazalpour A, Bennett B, Petyuk VA, Orozco L, Hagopian R, Mungrue IN, Farber CR, Sinsheimer J, Kang HM, Furlotte N, et al. Comparative analysis of proteome and transcriptome variation in mouse. *PLoS Genetics* 2011; 7:e1001393.
 107. de Moor CH, Richter JD. Translational control in vertebrate development. *Int Rev Cytol* 2001; 203:567-608; PMID:11131527; [http://dx.doi.org/10.1016/S0074-7696\(01\)03017-0](http://dx.doi.org/10.1016/S0074-7696(01)03017-0)
 108. Holcik M, Sonenberg N. Translational control in stress and apoptosis. *Nat Rev Mol Cell Biol* 2005; 6:318-27; PMID:15803138; <http://dx.doi.org/10.1038/nrm1618>
 109. Ivanov P, Anderson P. Post-transcriptional regulatory networks in immunity. *Immunol Rev* 2013; 253:253-72; PMID:23550651; <http://dx.doi.org/10.1111/imr.12051>
 110. Ruggiero D, Pandolfi PP. Does the ribosome translate cancer? *Nat Rev Cancer* 2003; 3:179-92; PMID:12612653; <http://dx.doi.org/10.1038/nrc1015>
 111. Kalkhoven CF, Muller C, Leutz A. Translational control of gene expression and disease. *Trends Mol Med* 2002; 8:577-83; PMID:12470991; [http://dx.doi.org/10.1016/S1471-4914\(02\)02424-3](http://dx.doi.org/10.1016/S1471-4914(02)02424-3)
 112. Spilka R, Ernst C, Mehta AK, Haybaeck J. Eukaryotic translation initiation factors in cancer development and progression. *Cancer Lett* 2013; 340:9-21; PMID:23830805; <http://dx.doi.org/10.1016/j.canlet.2013.06.019>
 113. Zhang C, Darnell RB. Mapping in vivo protein-RNA interactions at single-nucleotide resolution from HITS-CLIP data. *Nat Biotechnol* 2011; 29:607-14; PMID:21633356; <http://dx.doi.org/10.1038/nbt.1873>
 114. Jung H, Gkogkas CG, Sonenberg N, Holt CE. Remote control of gene function by local translation. *Cell* 2014; 157:26-40; PMID:24679524; <http://dx.doi.org/10.1016/j.cell.2014.03.005>
 115. Tcherkezian J, Brittis PA, Thomas F, Roux PP, Flanagan JG. Transmembrane receptor DCC associates with protein synthesis machinery and regulates translation. *Cell* 2010; 141:632-44; PMID:20434207; <http://dx.doi.org/10.1016/j.cell.2010.04.008>
 116. Leung KM, van Horck FP, Lin AC, Allison R, Standart N, Holt CE. Asymmetrical beta-actin mRNA translation in growth cones mediates attractive turning to netrin-1. *Nat Neurosci* 2006; 9:1247-56; PMID:16980963; <http://dx.doi.org/10.1038/nn1775>